What initial hormonal labs should be ordered for an incidentally discovered adrenal nodule?

Initial Hormonal Labs for Incidental Adrenal Nodule

All patients with an incidentally discovered adrenal nodule should undergo screening for autonomous cortisol secretion with a 1-mg overnight dexamethasone suppression test, and those with hypertension and/or hypokalemia should additionally be screened for primary aldosteronism with an aldosterone-to-renin ratio. 1

Universal Screening Required

Cortisol Excess (All Patients)

• 1-mg overnight dexamethasone suppression test is the preferred initial screening test 1
  • This is mandatory for every patient regardless of symptoms
  • A serum cortisol >50 nmol/L (1.8 µg/dL) after dexamethasone is abnormal 2
  • Values >138 nmol/L (>5 µg/dL) indicate "autonomous cortisol secretion" 2

The 2023 CUA/AUA guideline explicitly states that all patients with adrenal incidentalomas should be screened for autonomous cortisol secretion 1. This is critical because autonomous cortisol secretion occurs in 5-30% of incidentalomas and contributes to cardiovascular morbidity and mortality through progressive metabolic comorbidities 3.

Conditional Screening Based on Clinical Features

Primary Aldosteronism (If Hypertensive or Hypokalemic)

• Aldosterone-to-renin ratio (ARR) 1
  • Only required if patient has hypertension and/or hypokalemia
  • ARR >20-30 is suspicious and requires confirmatory testing 4, 5
  • Primary aldosteronism occurs in 5-6% of incidentalomas 3

Pheochromocytoma Screening (Selective)

The guidelines provide nuanced recommendations here:

• Do NOT screen if the lesion has unequivocal benign features (HU <10 on non-contrast CT) AND no signs/symptoms of catecholamine excess 1

• DO screen with plasma-free metanephrines or 24-hour urinary metanephrines if:

  • Lesion has >10 HU on non-contrast CT, OR
  • Patient has signs/symptoms of adrenergic excess (palpitations, headaches, diaphoresis, paroxysmal hypertension) 1

This selective approach is important because pheochromocytomas carry the highest mortality risk among adrenal tumors 6, yet universal screening is unnecessary for clearly benign lesions.

Androgen Testing (Rare Indication)

• Serum DHEA-S, testosterone, androstenedione 1
  • Only if suspected adrenocortical carcinoma OR clinical signs of virilization present
  • Not part of routine screening

Critical Pitfalls to Avoid

Never perform adrenal biopsy as part of initial workup 1. This is explicitly contraindicated and can cause:

• Tumor seeding if malignant
• Hypertensive crisis if undiagnosed pheochromocytoma
• Increased risk of progression and death 7

Do not skip pheochromocytoma screening before any surgical intervention, even if the lesion appears benign radiologically. Undiagnosed pheochromocytoma during surgery carries significant perioperative mortality risk 4.

Practical Algorithm

1. Order for ALL patients:

   • 1-mg overnight dexamethasone suppression test

2. Add if hypertensive or hypokalemic:

   • Aldosterone-to-renin ratio

3. Add if lesion >10 HU or symptoms of catecholamine excess:

   • Plasma-free metanephrines OR 24-hour urinary metanephrines

4. Add only if virilization or suspected ACC:

   • Sex hormone panel (DHEA-S, testosterone, androstenedione)

The strength of this approach is supported by multiple high-quality guidelines demonstrating that approximately 11-15% of incidentalomas are hormonally active 6, and identifying these lesions prevents significant morbidity and mortality from unrecognized hormone excess, particularly autonomous cortisol secretion which affects cardiovascular and metabolic outcomes 3, 2.